Gemzar

Gemzar is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide").
Gemzar is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.

Gemzar - Pharmacology:

Gemzar inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemzar is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemzar diphosphate inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Gemzar triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.

Gemzar mini report

Gemzar NDA
NDA - A product marketed under an approved New Drug Application
Gemzar INTRAVENOUS
INTRAVENOUS
Gemzar INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Gemzar HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Gemzar global name
Gemcitabine hydrochloride
Start - Stop data
START DATA:
1996-May-22
Start - Stop data
STOP DATA
not occurred

Gemzar for patients

General Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.

Laboratory Tests Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.

Gemzar Interactions

No specific drug interaction studies have been conducted. For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.

Gemzar Contraindications

Gemzar is contraindicated in those patients with a known hypersensitivity to the drug (see Allergic under ADVERSE REACTIONS).

Generic name, Overdose, Half Life Gemzar, Food Interactions, Chemical, etc..

Gemzar see also FDA report

Brand Names containing Gemcitabine